Tysabri May See Approval Delayed By FDA (Forbes) Piper Jaffray
Tysabri May See Approval Delayed By FDA (Forbes)
Piper Jaffray maintained a "market perform" rating and $14 price target on Irish drugmaker Elan.
« Milwaukee Journal Sentinel Brewers News and Notes Column: Book on | Main | Oculus Innovative Sciences Receives FDA Clearance for Over-the-Counter Marketing of »